ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0724

High Adherence to Angiotensin-Converting Enzyme Inhibitor in Children with Alport Syndrome: Objective Verification Using Liquid Chromatography Mass Spectrometry

Session Information

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology

Authors

  • Boeckhaus, Jan, Universitatsmedizin Gottingen, Göttingen, Germany
  • Gross, Oliver, Universitatsmedizin Gottingen, Göttingen, Germany
Background

Kidney failure (KF) in children and adolescents leads to reduced lifespan and compromised health. Alport syndrome (AS) is the second common genetic cause of KF. Angiotensin-converting enzyme inhibitors (ACEi) have demonstrated efficacy in delaying KF in young people living with AS, but non-adherence can compromise their therapeutic benefits. To investigate the adherence to ACEi in children and adolescents with AS, a liquid chromatography mass spectrometry (LCMS) based method was developed for objective verification of medication intake.

Methods

Urine samples from 58 children enrolled in the EARLY PRO-TECT Alport trial were analyzed. A LCMS based method was established and validated to simultaneously screen and quantify both ramipril and ramiprilat in urine samples. Participants were not informed in advance of the adherence measurements.

Results

109 urine samples from patients with early stages of chronic kidney disease (mean estimated glomerular filtration rate: 130 ± 32 ml/min/1.73m) were analyzed at two different time points. All 13 negative control samples (100%) were identified correctly. Adherence to ACEi therapy was consistently high, with 98% of children showing confirmed drug intake at both the initial (48/49) and second (44/45) measurements.

Conclusion

This study demonstrated that children with chronic kidney disease, when treated with ACEi within a clinical trial, maintain a high adherence to the prescribed medication.

Figure 1: Illustration of adherence to RASi. Donut graphs show the proportion of (A) the overall cohort of 107 measurements, including 13 negative controls (B) correctly identified negative controls (n=13, 100%). (C) adherence and non-adherence at both time points of the study (n=94; 98% adherence), (D) adherence and non-adherence at first adherence measurement (n=49; 98% adherence), (E) adherence and non-adherence at the second adherence measurement (n=45; 98% adherence)

Funding

  • Government Support – Non-U.S.

Digital Object Identifier (DOI)